1. Home
  2. MNRO vs ASMB Comparison

MNRO vs ASMB Comparison

Compare MNRO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Monro Inc.

MNRO

Monro Inc.

HOLD

Current Price

$21.26

Market Cap

623.8M

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$31.85

Market Cap

499.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNRO
ASMB
Founded
1957
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Automotive Aftermarket
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
623.8M
499.8M
IPO Year
1991
2010

Fundamental Metrics

Financial Performance
Metric
MNRO
ASMB
Price
$21.26
$31.85
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$17.67
$43.40
AVG Volume (30 Days)
618.4K
147.6K
Earning Date
01-28-2026
11-10-2025
Dividend Yield
5.38%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,190,710,000.00
$37,191,000.00
Revenue This Year
$0.22
$33.33
Revenue Next Year
$2.75
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
31.30
52 Week Low
$12.20
$7.75
52 Week High
$22.62
$39.71

Technical Indicators

Market Signals
Indicator
MNRO
ASMB
Relative Strength Index (RSI) 61.54 42.09
Support Level $20.58 $30.18
Resistance Level $21.09 $33.71
Average True Range (ATR) 0.72 1.69
MACD 0.01 -0.15
Stochastic Oscillator 94.67 29.72

Price Performance

Historical Comparison
MNRO
ASMB

About MNRO Monro Inc.

Monro Inc is an operator of retail tire and automotive repair stores in the United States. The company offers replacement tires and tire related services, automotive undercar repair services, and a broad range of routine maintenance services, on passenger cars, light trucks, and vans. It also provides other products and services for brakes; mufflers and exhaust systems; and steering, drive train, suspension, and wheel alignment.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: